| Project/Area Number |
06454218
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
MATSUSHIMA Kouji Kanazawa University Cancer Res, Inst. Professor, がん研究所, 教授 (50222427)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUNO Kouji Kanazawa University Cancer Res, Inst. Assistant, がん研究所, 助手 (40242565)
MUKAIDA Naofumi Kanazawa University Cancer Res, Inst. Assistant Professor, がん研究所, 助教授 (30182067)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥7,200,000 (Direct Cost: ¥7,200,000)
Fiscal Year 1995: ¥2,600,000 (Direct Cost: ¥2,600,000)
Fiscal Year 1994: ¥4,600,000 (Direct Cost: ¥4,600,000)
|
|---|
| Keywords | Interleukin 8 / Pathophysiology / Disease / Antibody / Treatment / Gene / NFkB / Anti-inflammatory drug / インターロイキン 8 / 炎症 / 組織破壊 / 好中球 / 受容体 / 転写 |
|---|
| Research Abstract |
A novel leukocyte chemotactic and activating factor, interleukin 8 (IL 8) was identified, biochemically purified, and molecularly cloned by us in 1987 at National Cancer Institute. Since then, we have established the essential involvement of IL 8 in various disease models in rabbits, including lung reperfusion injury, acute skin inflammation, and joint arthritis using a monoclonal antibody against IL 8. These works established for the first time an endogenously produced chemotactic factor has an essential role in causing inflammation. During the last two years studies, we further established that IL 8 is involved in serum sickness type glomerulonephritis and PPD-induced delayd type hypersensitivity. We also generated antibodies against murine as well as human IL 8 receptors and studied the expression on various types and maturation stages of leukocytes. We also examined the regulation of the expression of IL 8 receptors on T lymphocytes and found that IL 8 receptors are highly upregulated by treating with interferon gamma and TNF alpha. On the other hand, we previously revealed that NFkB in synergy with AP-1 or NF-IL 6 confers the responsiveness to various inflammatory stimuli to activate IL 8 gene. Here, wehave found that NFkB is an end target of the established anti-inflammatory and immunosuppressants, glucocorticoids and FK506. These observations indicate that novel anti-inflammatory drugs can be developed targeting the pathway (s) leadinf the activation of NFkB.To facilitate the approach, we developed LPS-dependent cell-free activation system of NFkB and identified a protein kinase which binds and specifically phosphorylates a negative regulator of NFkB, IkBa.
|
